comprehensive -WSS

comprehensive

author：focus 2025-09-28 02:28:01 - browse：6

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： HCA says smaller share of spending going to labor

knowledge

WSS

In areas with more Black doctors, Black people live longer

Disclosing genetic information: not as worrisome as once feared

Paxlovid study fails to answer questions over benefit for broader groups

Why drug prescriptions should include diagnoses

Why we need to separate burnout from moral injury in health care

3 hurdles to bringing medical devices to the U.S. market

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Sports medicine is finally prioritizing gender equality

Judge orders hearing on Trump's motion to disqualify Fulton County DA

Duchenne breakthrough therapy leaves behind pioneering families

Putin woos African leaders at a summit in Russia with promises of expanding trade and other ties

Virginia high school admissions case could be legal follow

With FDA staff opposed to Sarepta therapy, top official intervened

Virginia high school admissions case could be legal follow

HCA says smaller share of spending going to labor

Dobbs anniversary: the lost opportunity of abortion as health care

With FDA staff opposed to Sarepta therapy, top official intervened

entertainment

Many immigrants are left out of maternal health programs

New guidelines on severe brain injury complicate already difficult decisions

Adidas to release second batch of Yeezy sneakers after breakup with Ye

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

Judge orders hearing on Trump's motion to disqualify Fulton County DA

HCA says smaller share of spending going to labor

leisure time

knowledge

leisure time

hotspot